📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-14 17:32
225 analysed today
FollowTelegram
225
Today
149,626
All-time analysed
42,906
Positive
6,661
Negative
91,382
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Q1 PAT Drops 87% YoY to ₹0.43 Cr; Basic EPS at ₹0.37; New Statutory Auditor Proposed
Parnax Lab Ltd reported its Q1 (quarter ended June 30, 2026) consolidated net profit attributable to owners of ₹0.43 Cr (₹42.59 Lakhs), marking a steep decline from ₹3.27 Cr (₹326.88 Lakhs) in the year-ago period. Basic and diluted EPS for the quarter contracted to ₹0.37 compared to ₹2.85 in Q1 FY26 and ₹1.90 in Q4 FY26. In addition, the Board approved the appointment of M/s Ladha Singhal & Associates as statutory auditors for a 5-year tenure until the 2031 AGM, replacing retiring auditors M/s C N Patel & Co in line with statutory rotation norms. The company's 44th AGM is scheduled for September 29, 2026.
Confidence: HIGH
What changedParnax Lab reported a sharp YoY and QoQ contraction in Q1 net profit and initiated mandatory statutory auditor rotation.
Why it mattersThe severe quarterly profit contraction erodes TTM earnings run-rates and signals operational or margin pressures in the core formulations business.
Q1 Consolidated Net Profit (Owners): ₹42.59 LakhsQ1 Basic EPS: ₹0.37Q1 FY26 Net Profit (YoY base): ₹326.88 LakhsPaid-up Equity Capital: ₹1,148.56 LakhsAGM Date: September 29, 2026
📅 Short termEarnings performance is likely to create near-term pressure on the stock following the sharp sequential and YoY drop in net profit.
📈 Long termInvestors need to watch whether margin compression is temporary or structural for the company's formulation business across coming quarters.
⚠ Risk flags
- Severe margin and PAT contraction YoY and QoQ
- Earnings volatility
Key Highlights
Consolidated PAT attributable to owners dropped to ₹42.59 Lakhs from ₹326.88 Lakhs in Q1 FY26
Basic and diluted EPS declined to ₹0.37 per share vs ₹2.85 in Q1 FY26
Proposed appointment of M/s Ladha Singhal & Associates as Statutory Auditors for a term up to the 2031 AGM
44th Annual General Meeting convened for September 29, 2026 via VC/OAVM
👀 What to Watch
Track operational cost structures and revenue recovery in subsequent quarterly filings to assess if profitability stabilizes, and note the shareholder voting on auditor rotation at the AGM on September 29, 2026.
Parnax Lab Q1 Net Profit Drops ~87% YoY to Rs 0.43 Cr; Auditor Rotation Proposed
Parnax Lab reported a sharp drop in consolidated net profit attributable to owners to Rs 0.43 Cr (Rs 42.59 lakhs) for the quarter ended June 30, 2026, down from Rs 3.27 Cr in Q1 FY26 and Rs 2.18 Cr in Q4 FY26. Diluted EPS declined significantly to Rs 0.37 from Rs 2.85 in the year-ago quarter. The Board also approved the statutory auditor rotation, proposing M/s Ladha Singhal & Associates for a 5-year term through 2031, subject to shareholder approval. The 44th Annual General Meeting will take place on September 29, 2026.
Confidence: HIGH
What changedParnax Lab declared its Q1 FY27 financial results showing a sharp drop in net profit and proposed a change in statutory auditors due to mandatory term rotation.
Why it mattersA steep decline in quarterly net profit weakens trailing 12-month earnings run-rates for a small-cap pharma company (market cap Rs 153 Cr).
Q1 Net Profit (Attributable): Rs 42.59 lakhsQ1 FY26 Net Profit (Attributable): Rs 326.88 lakhsQ1 Diluted EPS: Rs 0.37Q1 FY26 Diluted EPS: Rs 2.85AGM Date: September 29, 2026
📅 Short termWeak quarterly earnings performance may create near-term pressure on the stock price.
📈 Long termLong-term trajectory depends on margin recovery in pharmaceutical formulations and effective working capital management given existing debt levels (D/E: 0.87).
⚠ Risk flags
- Steep quarter-on-quarter and year-on-year drop in operating profitability and net profit
- Debt burden of Rs 83 Cr relative to net worth of Rs 95 Cr
Key Highlights
Q1 Net Profit attributable to owners fell to Rs 42.59 lakhs from Rs 326.88 lakhs in Q1 FY26
Q1 EPS dropped to Rs 0.37 compared to Rs 2.85 in Q1 FY26 and Rs 1.90 in Q4 FY26
Total comprehensive income for the period stood at Rs 42.50 lakhs vs Rs 327.49 lakhs in Q1 FY26
Statutory auditor change to M/s. Ladha Singhal & Associates proposed for a 5-year tenure up to 2031
44th Annual General Meeting scheduled for September 29, 2026
👀 What to Watch
Track whether margin compression is temporary and watch for full revenue details and operational commentary during the AGM on September 29, 2026.
